Since numerous basic studies have suggested TSLP is a promising therapeutic target against AD and other allergic diseases, further clinical trials are required to validate whether TSLP-targeting therapies could prevent the progression of AD, which is expected to improve AD patients' quality of daily life and alleviate AD-related allergic disorders. Here, TSLP is linked to Alzheimer disease.